摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-((1,4)-trans-4-hydroxycyclohexyl)isobutyramide | 94285-57-1

中文名称
——
中文别名
——
英文名称
N-((1,4)-trans-4-hydroxycyclohexyl)isobutyramide
英文别名
——
N-((1,4)-trans-4-hydroxycyclohexyl)isobutyramide化学式
CAS
94285-57-1
化学式
C10H19NO2
mdl
——
分子量
185.266
InChiKey
WYUDGBPGXYVNKA-KYZUINATSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    367.5±31.0 °C(Predicted)
  • 密度:
    1.03±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.06
  • 重原子数:
    13.0
  • 可旋转键数:
    2.0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.9
  • 拓扑面积:
    49.33
  • 氢给体数:
    2.0
  • 氢受体数:
    2.0

文献信息

  • NEW COMPOUNDS
    申请人:Stadtmueller Heinz
    公开号:US20110237598A1
    公开(公告)日:2011-09-29
    The present invention encompasses compounds of general formulae (1 a ) and (1 b ) wherein the groups R 1 to R 5 , A, Q, m, n, p and q are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use as medicaments.
    本发明涵盖通式(1a)和(1b)的化合物,其中R1到R5,A,Q,m,n,p和q的定义如权利要求1所述,适用于治疗因细胞过度或异常增殖而特征化的疾病,并作为药物使用。
  • TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS
    申请人:Fales Kevin Robert
    公开号:US20100022550A1
    公开(公告)日:2010-01-28
    The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of formula (I).
    本发明提供了以下公式的化合物:公式(I)或其药学上可接受的盐;包含有效量公式(I)化合物与适当载体、稀释剂或赋形剂的制剂;以及治疗生理障碍,特别是虚弱,骨质疏松,骨质疏松症和男女性功能障碍的方法,包括向需要的患者给予公式(I)化合物的有效量。
  • OXIME COMPOUNDS AND THE USE THEREOF
    申请人:Matsumura Akira
    公开号:US20090298878A1
    公开(公告)日:2009-12-03
    The invention relates to oxime compounds of Formula (I) and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X is hydrogen, optionally substituted aryl, optionally substituted heteroaryl or the like; Y is CO, SO 2 , CR 3 R 4 or the like; Z is optionally substituted lower alkyl, optionally substituted aryl or the like; W is optionally substituted lower alkylene or optionally substituted lower alkenylene, R 3 and R 4 are each independently hydrogen, lower alkyl or the like; p is 0, 1, or 2 and q is 0, 1 or 2. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.
    本发明涉及式(I)的化合物及其药学上可接受的盐、前药或溶剂,其中X为氢、可选取代芳基、可选取代杂环基或类似物;Y为CO、SO2、CR3R4或类似物;Z为可选取代的低烷基、可选取代的芳基或类似物;W为可选取代的低烷基或可选取代的低烯基,R3和R4各自独立地为氢、低烷基或类似物;p为0、1或2,q为0、1或2。本发明还涉及使用式(I)的化合物来治疗、预防或改善对通道封锁有反应的疾病,特别是N型通道。本发明的化合物特别适用于治疗疼痛。
  • ORGANIC COMPOUNDS
    申请人:Nabriva Therapeutics AG
    公开号:EP2321272B1
    公开(公告)日:2016-04-20
  • US7320986B2
    申请人:——
    公开号:US7320986B2
    公开(公告)日:2008-01-22
查看更多